SGEN Seattle Genetics Inc.

71.14
-0.34  -0%
Previous Close 71.48
Open 71.15
Price To Book 8.97
Market Cap 11422326187
Shares 160,561,234
Volume 218,844
Short Ratio
Av. Daily Volume 923,329

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 trial to be initiated.
SGN-LIV1A (I-SPY 2)
Neoadjuvant for newly diagnosed Stage 2 or 3 HER2 negative breast cancer
Phase 1/2 trial initiated early 2018.
SGN-LIV1A + KEYTRUDA
First-line triple negative breast cancer (TNBC)
Phase 2 enrolment to be completed mid-2019.
Tisotumab Vedotin (innovaTV 204 )
Cervical Cancer
Phase 2 pivotal data due 1Q 2019.
Enfortumab vedotin - EV201
Urothelial cancer
Phase 3 trial initiated 2Q 2017.
ADCETRIS and Opdivo
Relapsed Hodgkin Lymphoma
Phase 3 trial initiated mid-2017. Data from Phase 1/2 at ASH 2017 showed a 83% ORR and 62% CR.
ADCETRIS and Opdivo CM-812
Relapsed Hodgkin Lymphoma
Approval announced August 19, 2011.
ADCETRIS
Hodgkin lymphoma and Anaplastic large cell lymphoma
Phase 1/2 clinical hold placed on December 27, 2016 was lifted March 6, 2017. Enrollment halted June 19, 2017 due to safety.
Vadastuximab Talirine (SGN-CD33A)
Myelodysplastic syndrome (MDS)
Phase 1b updated data at SABCS December 7, 2017.
(Tucatinib ONT-380) and T-DM1
HER2+ Metastatic Breast Cancer (MBC)
Phase 2 data due 2019.
(Tucatinib ONT-380) + Herceptin and Xeloda - HER2CLIMB trial
HER2+ Metastatic Breast Cancer (MBC)
Phase 3 trial discontinued due to higher rate of deaths - June 19, 2017.
Vadastuximab Talirine (CASCADE)
Acute myeloid leukemia (AML) - cancer
sBLA approval announced March 20, 2018. PDUFA date under priority review was May 1, 2018.
ADCETRIS in combination with chemotherapy ECHELON-1
Frontline Hodgkin lymphoma
Phase 2 trial initiated 3Q 2016.
SGN-CD19A
Frontline DLBCL cancer
FDA Approval announced November 16, 2018.
ADCETRIS in combination with chemotherapy - ECHELON-2
Frontline CD30-positive mature T-cell lymphomas - cancer
Approved August 17, 2015 under priority review.
ADCETRIS - AETHERA
Post-transplant Hodgkin lymphoma (HL) cancer
Approval announced November 9, 2017.
ADCETRIS
Cancer - ALCANZA trial for relapsed CD30-positive cutaneous T-cell lymphoma
Phase 1b trial has been initiated - noted February 6, 2018.
Enfortumab vedotin and pembrolizumab
2nd-line Urothelial cancer
Phase 1b/2 trial has been initiated.
Ladiratuzumab Vedotin
Triple negative breast cancer (TNBC)
Phase 3 trial initiation announced July 9, 2018.
Enfortumab vedotin - EV-301
Urothelial cancer
Phase 2 dosing has commenced - noted July 12, 2018.
Tisotumab Vedotin (innovaTV 207)
Solid tumors
Phase 1/2 updated data presented at ESMO October 20. 2018.
Tisotumab Vedotin (innovaTV 201)
Recurrent Cervical Cancer
Phase 1 data February 11, 2019 noted ORR 42%.
Enfortumab vedotin EV-101
Urothelial cancer

Latest News

  1. Biotech Hedge Fund Bailed on Drugmaker Before Its Depression Treatment Scored
  2. Biotech Stock Roundup: Regeneron Impresses in Q4, Gilead Slumps, MacroGenics Soars
  3. New Research: Key Drivers of Growth for Phillips 66, Seattle Genetics, Green Plains, C&J Energy Services, FRP, and Medical Transcription Billing — Factors of Influence, Major Initiatives and Sustained Production
  4. Edited Transcript of SGEN earnings conference call or presentation 7-Feb-19 9:30pm GMT
  5. Seattle Genetics' Adcetris Gets EC Nod for Label Expansion
  6. Seattle Genetics Achieves $30 Million Milestone Payment for European Commission Approval of ADCETRIS® (Brentuximab Vedotin) in Frontline Hodgkin Lymphoma
  7. Why Goodyear Tire & Rubber, Henry Schein, and Seattle Genetics Slumped Today
  8. Can This Biotech's Only Drug Meet Its 'Multi-Blockbuster Potential'?
  9. Seattle Genetics (SGEN) Q4 Loss Widens, Revenues Top Mark
  10. Seattle Genetics Looks to Make Adcertis a Blockbuster; Investors Unimpressed
  11. Seattle Genetics (SGEN) Q4 2018 Earnings Conference Call Transcript
  12. The Daily Biotech Pulse: Big Miss For Seattle Genetics; Hematology Conference Presentations; Gossamer Bio, Harpoon IPOs
  13. See what the IHS Markit Score report has to say about Seattle Genetics Inc.
  14. Seattle Genetics (SGEN) Reports Q4 Loss, Tops Revenue Estimates
  15. Seattle Genetics: 4Q Earnings Snapshot
  16. Seattle Genetics Reports Fourth Quarter and Full Year 2018 Financial Results
  17. Stocks Moving After Hours: Mattel, Skechers, Columbia Sports
  18. Seattle Genetics to Present at Guggenheim Healthcare Talks Idea Forum | Oncology Day
  19. What's in the Cards for Glaxo (GSK) This Earnings Season?
  20. Regeneron (REGN) to Report Q4 Earnings: Is a Beat in Store?